A phase I study of weekly docetaxel (DTX) and biweekly oxaliplatin (Ox) in patients with advanced solid tumours

2098 Background: DTX and Ox are active against a wide range of tumour types. DTX is usually administered in a 3 weekly schedule, resulting in the dose limiting toxicity of myelosuppression. This may be reduced by weekly administration. The main dose-limiting toxicity (DLT) of Ox is transient acute dysaesthesia and cumulative peripheral neuropathy. In view of pre-clinical evidence of synergy between DTX and Ox, we have conducted this phase I trial. Methods: Patients for whom treatment with DTX was indicated were eligible. DTX was given on days 1, 8, 15, 22, 29 and 36 and Ox administered on days 1, 15 and 29 of an 8 week schedule at starting doses of DTX 20 mg/m2 and Ox 65mg/m2. Results: To date 16 patients, median age 55 years, have been recruited. Primary disease sites: upper GI (12 patients), small bowel (1), squamous cell skin (1), epithelioid sarcoma (1) and unknown (1). Patients were treated as follows: dose level (DL)1 - 3 patients, DL2 - 6 patients, DL3 - 3 patients, DL-3 - 4 patients (1 patient did...